Forum Topics BOT BOT Forecast breakeven date pushed

Pinned straw:

Added a month ago

Im not sure if this update from Simply Wall St has had an effect on BOT share price today. Down circa 5% this morning.

I can't see any further detail on the reasoning.

ad52446f7a4ac54f0f351d361312add463970d.jpeg

mikebrisy
Added a month ago

@Arizona @Schwerms @Nnyck777 @NewbieHK as far as I know, there is no new information in the market beyond i) their initial sales data, ii) the tariff response and iii) MC standing aside due to health.

I'm going to put forward 2 possible explanations, stating up front that I don't know which one, if either, is valid:

EXPLANATION 1

According to my marketscreener.com report, there has been one analyst dropping coverage very recently. (see below)

Prior to early April, Euroz Harley and Evans and Partners has PT of $0.80 and $0.50, respectively, for an average of $0.65.

If the $0.80 PT is the graph below is EH (which makes sense because the EH updates appear in the MarketScreener.com newsfeed) then the picture below would imply that they have dropped coverage. However, their $0.80 PT still appears as live in the tradingview.com analyst summary. So, this doesn't make sense.

So, perhaps (for some reason) EH has stopped feeding news aggregators like marketscreener.com and Simply Wall Street. Remember that Simply Wall Street is algorithmic, so if it stopped getting a feed, and was left with the less optimistic forecast, this could have the impact on the reported financial forecast as showing the breakeven pushing out to FY27. Even though no-one (in that scenario) would actually have changed their forecast.

So my first exaplanation is that some market participants might be reacting to data integrity issues in several the of the aggregation services.

As I said, I don't know what is factually correct here, and I am just trying to make sense of things.

50be1d8276ca88f9c57cd8eb9924f89c8c5eaf.png


Explanation 2

Hot money getting impatient and supply of shares due to short selling.

Following relative quiet after the initial sales data, there has perhaps been some short term money taking profits from the cap. raise discount at $0.33 or simply some investors getting impatient. As one of you said, perhaps there was an expectation of a quick multibagger. Once the short term chart starts to turn, the stock starts appear on a number of technical filters, and technical trading "talking heads" as "sell". This happens more often than not with biotechs.

We have also recently see some significant short interest building up(see below), and that will be increasing supply at a time of no new information - which would exacerbate downwards price pressure.

230ea90704bb31f4b06f3d8d2469704bc73a43.png


My Conclusion

I am pretty much ignoring all of this, since, as far as I can see, it is based on no actual information.

What I am interested in is whether $BOT issues a revenue trading update for 1H. Within a week or two - based on script weekly run rates - they'd be in a position to give a pretty tight revenue number, and publish the weekly charts for number of scripts, and number of prescribers. This would add another 8 or 9 weeks of data to the initial series we had. From my perspectively, such information will be hugely valuable as it would allow us to see whether:

a) They remain in a accelerating phase of the S-curve (potentially a massive catalyst for the SP)

b) Whether they are entering the "linear' phase of the S-curve (a big catalyst from where we are in today's SP)

c) Whether momentum is stalled. .... trickier.


I don't know whether $BOT observe the period end "blackout". Becuase if they do, such a trading update will need to come out in the next week or maybe two.

In any event, all I care about is real performance data. As for the rest, the market will do what the market will do.


Disc: Held.


31

Schwerms
Added a month ago

@mikebrisy makes a lot of sense your explanation 2.

In your experience are 1H trading updates common at this stage of a launch?




19

mikebrisy
Added a month ago

It varies hugely. Some companies play a straight bat and report only when required, whereas others are super-focused on where they stand compared with market expectations and continuous disclosure obligations.

On balance, if sales were still accelerating, that would be creating a big gap between SP and fair value. So I’d expect an update. No update implies management consider they don’t have information which is material to the SP.

its really hard to tell.

If pushed, I think there will soon be a trading update.

26

Schwerms
Added a month ago

@mikebrisy where does the push for the update come from? Euroz? Or would larger holders push for it

12

mikebrisy
Added a month ago

@Schwerms Companies vary widely in when and why they choose to release “out-of-cycle” updates, often called Trading Updates. In my experience, each Board and CEO tends to take their own approach, some with a tendancy to over-communicate, and some to under-communicate.

Legally, Boards are required to disclose any information that could materially affect the share price - this is part of their continuous disclosure obligations. But in practice, some companies report even minor developments, while others only issue updates when absolutely necessary, choosing to wait for formal half-year or full-year reports.

Beyond legal duties, management often want the share price to reflect what they believe is the company’s fair value. For example, if the share price drops 50% without a fundamental reason and an acquirer makes a takeover offer at a 50% premium to that lower price, the Board would struggle to reject it - even if they believe the business is worth much more. This is why keeping the market informed is crucial.

Investor Relations plays a central role here: ensuring all valuation-relevant information is shared so the stock isn’t undervalued. Sometimes, this turns into a proactive push by management to “educate” the market and close a perceived value gap.

That said, there’s a fine line. If leadership strongly believes the market is undervaluing the company, they may become overly promotional. This becomes more complicated when executive incentives - like option schemes tied to total shareholder return - create pressure to push the share price higher, even if temporarily.

So, the decision to issue a Trading Update often comes down to the mindset of the Board and management. If they believe the company is significantly undervalued, as I suspect is currently the case with Botanix ($BOT), they’ll be considering the timing and nature of any potential update.

For example, if Sofdra is performing strongly (and to be clear, we don’t know that yet), management will weigh two options:

  • Issue a Trading Update now if they believe the share price is clearly too low based on new sales data, or
  • Wait a few weeks and provide a fuller update, including revenue figures and possibly forward guidance, as the regular half-year.


Given how open they were ahead of Sofdra’s launch, and the updates they've provided since, I think an update is likely.

On continuous disclosure more generally: companies that give forward guidance are obligated to update the market if results deviate from those expectations. While $BOT hasn’t released formal guidance, both Howie and Matt have made supportive public comments suggesting FY26 revenue is on track to exceed $100 million. Unless we hear otherwise, it’s fair for shareholders to assume that expectation still holds.

In short: no news likely means nothing has materially changed. Which is where I am, and why I am unfussed about the short term SP drop. (Albeit, I am worried that they get acquired too cheaply!)

21
Schwerms
Added a month ago

Feels to me like some of the short sellers closing out, this drop has gotten a bit out of hand, the volume has been big over the last week.

I got some more today at 29 and 30..

Fundamentals to me are unchanged but it does hurt to look at right now.

I've done some work on being cash flow positive and at the current rate it's Q4 this calendar year assuming we get near $100m annual costs and stay on the current trajectory we last saw and including payment lag from the insurers.

I'll double check my numbers and post it tonight if I get a chance.

Maybe some tariff and MFN related selling but a minimal and no affect.

Would be easy to sell if you didn't have strong conviction with the recent drops from the high.

26

Arizona
Added a month ago

@Schwerms Agreed. There is nothing I have seen that would change my view re the fundamentals.

At the same time, I didn't expect the cap Raise or Matt's exit. Put a few of these things like this together and it can make one more thoughtful.

Well done on purchasing more stock today.

18

Schwerms
Added a month ago

It's only a temporary leave and apparently he's had health problems in the past according to HC but I haven't tried to verify that.

15
Nnyck777
Added a month ago

The same site that had this as fair value of $7.00? I am dubious. This sell off feels orchestrated! Below pre FDA approval levels. BOT was already well ahead of Euroz Hartley’s prediction if it stays on track.

15

Arizona
Added a month ago

@Nnyck777 Yes I remember them having a "fair value" up over $8 at one stage. Currently at precisely $4.23.

I don't hold much stock in their valuation, I just wondered if it was enough to spook the horses a little, as the timing of its release seemed to coincide with a further 5% drop.

SP has recovered a little now and buyers and sellers have evened out. Perhaps it's all part of an orchestrated sell off, as you say.

15

NewbieHK
Added a month ago

I am guessing that some of the recent selling pressure has come from a few of the retail “next hot stock” followers who, had hoped that this was going to have a DRO kind of run up.

Consequently, they are leaving now, realising the muti-bags are not going to come as quick as they had believed ie in a few weeks or few months. So off they head for the next “hot stock”.

Anyway, I guess it has provided an opportunity for those who were happy with the recent update, to start a position or top up.

25